id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-0093-0006,FDA,FDA-2013-N-0093,"Agency Information Collection Activities: Proposed Collection;
Comment Request; Evaluation of the Program for Enhanced Review
Transparency and Communication for New Molecular Entity New Drug
Applications and Original Biologics License Applications in Prescription
Drug User Fee Acts",Notice,60 Day Proposed Information Collection,2015-12-10T05:00:00Z,2015,12,2015-12-10T05:00:00Z,2016-02-09T04:59:59Z,2015-12-10T17:15:29Z,2015-31100,0,0,0900006481d9ab7a
FDA-2013-N-0093-0004,FDA,FDA-2013-N-0093,Meetings: Interim Assessment of the Program for Enhanced Review Transparency and Communication,Notice,Meeting,2015-04-22T04:00:00Z,2015,4,2015-04-22T04:00:00Z,2015-07-01T03:59:59Z,2015-06-25T01:30:38Z,2015-09300,0,0,0900006481ab3685